has_Ingredient has_MoA has_PE drug associated with AE in adult drug associated with AE in senior used to treat disease Cellular Division Phase Alteration [PE] Increased Cellular Death [PE] erlotinib [Chemical/Ingredient] E [Preparations] Vascular Growth Decrease [PE] HER1 Antagonists [MoA] Cellular Growth Phase Reduction [PE] ERLOTINIB http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf erlotinib J4T82NDH7E 4021511 <VANDF_Record>50.416^4203^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4203</VA_IEN> <VANDF_Record>50.6^4033^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4033</VA_IEN> C1135135 C273486 Ingredient 337525 Active N0000148872 ERLOTINIB pancreatic cancer non-small cell lung carcinoma fatigue AE dyspnea AE fever AE rash AE infection AE myalgia AE anorexia AE abdominal pain AE bone pain AE weight loss AE edema AE nausea AE vomiting AE constipation AE stomatitis AE diarrhea AE